Evidence map›Paper›PMID 31031425›Full record

ArticleTetrahedron letters2018

Protected pyrimidine nucleosides for cell-specific metabolic labeling of RNA.

Samantha Beasley, Kim Nguyen, Michael Fazio, Robert C Spitale

Abstract read
In one paragraph

Article in Tetrahedron letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Samantha BeasleyDepartment of Pharmaceutical Sciences, University of California, Irvine. Irvine, California 92697.
Kim NguyenDepartment of Pharmaceutical Sciences, University of California, Irvine. Irvine, California 92697.
Michael FazioDepartment of Pharmaceutical Sciences, University of California, Irvine. Irvine, California 92697.
Robert C SpitaleDepartment of Pharmaceutical Sciences, University of California, Irvine. Irvine, California 92697.

Funding

CARCINOGENESIST32CA009054 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI EDINGER, AIMEE L, FRUMAN, DAVID ALEXANDER · 1985 to 2025
$8.6M
Cracking the RNA Localization CodeDP2GM119164 · NIGMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI SPITALE, ROBERT C · 2015 to 2015
$2.2M
Multicellular simultaneous chemotranscriptomic profiling of nascent transcription during learningR21MH113062 · NIMH · UNIVERSITY OF CALIFORNIA-IRVINE · PI SPITALE, ROBERT C · 2017 to 2018
$425k
NCI NIH HHS T32 CA009054NIGMS NIH HHS DP2 GM119164NIMH NIH HHS R21 MH113062
6 · The paper itself

Abstract

RNA molecules can perform a myriad of functions, from the regulation of gene expression to providing the genetic blueprint for protein synthesis. Characterizing RNA expression dynamics, in a cell-specific manner, still remains a great challenge in biology. Herein we present a new set of protected alkynyl nucleosides for cell-specific metabolic labeling of RNA. We anticipate these analogs will find wide spread utility toward the goal of understanding RNA expression in complex cellular and tissue environments, even within living animals.

Indexed as

Alkynyl NucleosidesMetabolic LabelingRNA

Identifiers

PMID31031425
PMCPMC6483386

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.